⚠️ Recall notice, as of 23 October 2026: FreeStyle Libre 3 and Libre 3 Plus are under an FDA Class I recall, the most serious category. Affected sensors can report glucose values lower than actual blood glucose. As of 7 January 2026, Abbott has reported 860 serious injuries and 7 deaths to the FDA. The FDA instructs users to stop using affected sensors immediately and dispose of them.
Germany is in scope: Abbott says a subset of sensors shipped in Germany is affected, the FDA lot list has separate tabs for products inside and outside the US, and Germany’s medical device regulator BfArM published the German manufacturer notice on 25 Nov 2025 (BfArM 55464/25). Check your serial number yourself: Lot checker, falsely low (Class I, Libre 3 + 3 Plus) · Lot checker, falsely high (Libre 3 Plus only) · FDA recall page. In the lot checker, select the country where you obtained the sensor.
Separately, there is a second issue with falsely high readings on the Libre 3 Plus, covered by its own BfArM notice 42777/25. Alternatives available in Germany are the Dexcom G7 and Dexcom Flex from Dexcom’s web shop, both intended for people with diabetes per the manufacturer; Stelo (designed for non-diabetics) is sold only in the US — more below.
Transparency: No first-party glucose measurements were taken for this article. It is based on manufacturer specifications, regulatory and product documentation, and published studies — each named in the text. More on methodology
Blood sugar is one of the most underestimated performance factors — even for people without metabolic disease. Glucose spikes affect energy, focus, sleep quality and mood, and most people have never seen what their own curve looks like after a meal.
The FreeStyle Libre 3 is the sensor most Europeans start with when they want to change that. This article answers the three questions worth settling first: what it costs, how a non-diabetic legally gets one, and what the benefit is realistically worth.
What Is a CGM and How Does the Libre 3 Work?
A Continuous Glucose Monitor (CGM) continuously measures glucose in the interstitial fluid under your skin. No finger pricks, no manual testing. The sensor sits on your upper arm and transmits readings to your smartphone automatically.
The FreeStyle Libre 3 by Abbott was the first generation to stream continuously over Bluetooth instead of requiring a scan — one reading per minute, straight into the app.
How it sits: A flat plastic sensor (roughly 21 mm diameter, 2.9 mm high per Abbott’s datasheet) whose filament is placed just under the skin with an applicator.
Wear time: 14 days per sensor. The Libre 3 Plus runs up to 15 days. The Libre 3 has not been phased out: according to Abbott Germany, self-payers and privately insured customers have only been able to buy the Libre 3 Plus since 15 October 2024, while people with statutory insurance are still supplied with the Libre 3; Abbott says contracts with statutory insurers for the 3 Plus are being signed step by step.
Accuracy: In Abbott’s pivotal study (Alva et al., Journal of Diabetes Science and Technology, 2022, presented at the ADA Scientific Sessions) the system reached a MARD of 7.9% across all age groups, and 7.6% in adults. MARD (Mean Absolute Relative Difference) is the mean percentage deviation from a laboratory blood glucose reference — lower is better. At the time that was the lowest published figure for a 14-day sensor.
Cost: as a self-payer in Germany you get the Libre 3 Plus at €70.60 per sensor (Abbott, as of 23 Oct 2026), €4.71 per day over 15 days. Reimbursed for diabetics with a documented medical indication — for everyone else, out of pocket.
Why Does This Make Sense for Non-Diabetics?
Because a “normal” fasting blood sugar is no guarantee of unremarkable glucose dynamics across the day.
The strongest evidence here comes from Stanford: Hall et al. published “Glucotypes reveal new patterns of glucose dysregulation” in PLOS Biology in 2018. They put CGMs on people classified as normoglycemic and found they cluster into distinct “glucotypes”. Participants with the pattern classified as severe spent up to 15% of the time in the prediabetic range and around 2% in the diabetic range despite unremarkable standard diagnostics. Identical standardised meals produced wildly different curves between individuals.
That is precisely the case for wearing a CGM without diabetes: a fasting value at your GP does not surface that spread.
These glucose spikes are associated in the literature with:
- Energy crashes (the classic post-lunch slump)
- Worse sleep quality from evening spikes
- Food cravings after quickly-digested carbs
- Focus problems after a meal
- Long-term: increased insulin resistance risk
Worth flagging: most of these links are associative, not causally established. A CGM shows you patterns, not diagnoses.
What You Can Actually Do With the Data
The three interventions with the best evidence behind them — and the ones a sensor lets you verify against your own curve:
1. Meal composition beats calorie counting
Pairing carbohydrates with protein, fat or fibre measurably flattens the postprandial curve. That is the practical core of the Stanford glucotype data: not “oats are bad”, but “your response to oats is individual and modifiable”. A sensor answers that question for you personally instead of inferring it from population averages.
2. Movement after meals
The most cleanly quantified intervention. The meta-analysis by Buffey et al. (Sports Medicine, 2022, vol. 52, pp. 1765–1787) compared prolonged sitting against short interruptions: light-intensity walking lowered glucose by roughly 17% on average versus uninterrupted sitting, while simply standing achieved only around 9.5%. Bouts as short as two to five minutes showed an effect. Muscle tissue takes up glucose independently of insulin — a simple, well-documented mechanism.
3. Carbohydrate timing
Late carb-heavy meals and overnight glucose variability are repeatedly associated with fragmented sleep in observational data. The evidence here is thinner than for point 2 — the link is plausible and well documented, but the direction of causation is not settled. If you already track HRV and sleep, this is something you can check against your own data.
What to watch in the app
- Time-in-Range 70–140 mg/dL — a realistic target corridor for a non-diabetic
- Post-meal peak — a return to baseline within roughly two hours is considered a good marker
- Overnight curve — a flat line is the goal; heavy oscillation points to nutrition or sleep issues
- Morning fasting value — chronically above 100 mg/dL belongs with a doctor, not with self-interpretation
How Non-Diabetics Can Get the Libre 3
In Germany the sensor is neither prescription-only nor pharmacy-only. The German regulation on dispensing medical devices (MPAV) restricts to pharmacies only prescription-only devices, devices containing pharmacy-only substances and the products in its Annex 2 (haemodialysis concentrates); CGM sensors are none of these, and a German online pharmacy lists the Libre 3 Plus as “Apothekenpflicht: Nein”. You do not need a prescription to buy one — the prescription only decides whether your insurer pays. As a self-payer you get the Libre 3 Plus; Abbott has not sold the Libre 3 to self-payers since 15 Oct 2024.
- Abbott web shop: order directly as a self-payer, no prescription, one-off or in the PlusService subscription
- Pharmacy, local or online: the Libre 3 Plus is listed under PZN 19383498; the online pharmacies we checked on 23 Oct 2026 showed €70.60, availability varied
- Prescription only matters for reimbursement: coverage requires a doctor-documented diabetes indication. Without one you self-pay regardless.
Access rules differ elsewhere in Europe and in the US — check the local classification before ordering.
Realistic cost: €70.60 per 15-day Libre 3 Plus sensor, or €4.71 per day. Abbott’s subscription ships 26 sensors a year, which comes to €1,835.60 a year.
Is It Worth It?
Yes, if:
- You take performance optimization seriously
- You experience energy crashes, post-lunch slumps, or food cravings
- You want to understand how your body responds to specific meals
- You’re willing to turn the data into actual behaviour change
No, if:
- You’ll just wear the sensor without changing any behavior
- You expect medical diagnoses (CGM is not a diagnostic device)
- You want to track permanently without having budgeted for the running cost
The honest read: the learning curve is steep for the first four to six weeks and flattens hard after that. Once you know your individual patterns you don’t need a permanent subscription — periodic check-in cycles are enough.
Alternatives to the Libre 3
Dexcom G7
The direct competitor. In its pivotal study (Garg et al., 2022) the arm-worn sensor reached a MARD of 8.2%. Wear time 10 days. Prices, intended use and the cheaper Dexcom Flex are covered in our Dexcom overview for Germany.
Stelo (by Dexcom)
The first CGM explicitly cleared for non-diabetics — FDA-cleared in March 2024 as the first over-the-counter CGM in the US. Its app is built around lifestyle tracking rather than clinical metrics. Not available in Germany or the EU: Stelo is sold only in the US (as of 14 Oct 2026).
Abbott Lingo
Abbott’s own consumer product on the same sensor platform as the Libre 3 — the difference is the coaching app, not the hardware. Available in the UK since January 2024, not officially launched in Germany as of July 2026. Details in our Lingo vs Libre 3 Plus comparison.
Note: Supersapiens, long the default CGM entry point for endurance athletes, ceased operations in March 2024 and no longer ships sensors.
Sources for price, availability and recall
All accessed on 23 Oct 2026:
- Abbott Germany, FreeStyle Libre 3 Plus sensor (€70.60 per sensor for self-payers, 26 sensors per year in the PlusService subscription, insurer contracts signed “step by step”): freestylelibre.de
- Abbott Germany, FreeStyle Libre 3 sensor (only Libre 3 Plus for self-payers and private patients since 15 Oct 2024): freestylelibre.de
- Abbott Germany, FAQ “Preise der Sensoren”: freestylelibre.de
- German online pharmacies, PZN 19383498 at €70.60: apobring.de (legal status “frei verkäuflich”, “Apothekenpflicht: Nein”) · amamed.de · aponeo.de (listed as unavailable)
- German Medical Device Dispensing Regulation (MPAV), § 3 and Annex 2: gesetze-im-internet.de
- FDA recall page (Class I, 860 serious injuries and 7 deaths as of 7 Jan 2026): fda.gov
- Abbott, German FAQ on falsely low readings (subset of sensors shipped in Germany affected): freestylecheck.com/de-de
- BfArM notices 55464/25 (Libre 3 and 3 Plus, published 25 Nov 2025) and 42777/25 (Libre 3 Plus, falsely high, published 15 Sep 2025)
Keep reading
Related articles on this topic: